LevoFLOXacin

C. diff Risk

High

Oral Bioavailability

Excellent

Approximate Cost

Non-formulary

Dosing

250-750mg PO/IV daily

CrCl Greater Than 50 mL/minCrCl 20 - 49 mL/minCrCl 0 - 19 mL/min750mg PO/IV daily750mg PO/IV q48h750mg once then 500mg PO/IV q48h

750mg IV/PO load then 500mg q48h

750mg IV load then 500mg daily

May increase if larger flow rate

General Information

Monitor QTc in patients with increased risk

  • QTc prolongation

  • Dysglycemia

  • Rash

  • Tendinopathy and rupture

  • GI upset

  • Weakness exacerbation in myasthenia gravis

  • CNS toxicity including confusion, psychosis

  • Other QTc prolonging agents

  • Divalent cations - Decreased absorption (ex: calcium, magnesium)

  • NSAIDs - Increase seizure risk

  • Warfarin - Increased INR

Antimicrobial class: Fluoroquinolone

Pregnancy category: C

Average serum half life: 7 hours

Biliary penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Therapeutic

  • Lower respiratory infection (CAP, HAP)

  • Intraabdominal infection

Levofloxacin is non-formulary at MSH. Levofloxacin will be automatically substituted to Moxifloxacin for non-UTI indications or to Ciprofloxacin for UTI indications.